VNDA Vanda Pharmaceuticals Inc.

15.94
-0.98  -6%
Previous Close 16.92
Open 16.8
52 Week Low 9
52 Week High 21.8627
Market Cap $886,872,366
Shares 55,638,166
Float 44,555,408
Enterprise Value $557,230,387
Volume 318,459
Av. Daily Volume 497,660
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Tradipitant
Gastroparesis
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Tradipitant - ODYSSEY VLY-686-3501
Pneumonia associated with COVID-19
Phase 3
Phase 3
Phase 3 data August 18, 2020 noted statistically significant improvement by Day 7. However, improvement was not statistically significant at Day 28. Announced August 3, 2021 that enrollment will be closed due to futility.
FANAPT (iloperidone)
Bipolar Disorder
Phase 3
Phase 3
Phase 3 trial currently enrolling patients as of July 2021.
HETLIOZ (tasimelteon)
Delayed sleep phase disorder (DSPD)
Phase 3
Phase 3
Phase 3 trial currently enrolling as of July 2021.
FANAPT (iloperidone)
Maintenance treatment of schizophrenia in adults
Approved
Approved
Approved May 26, 2016.
VSJ-110
Allergic Conjunctivitis
Phase 2
Phase 2
Phase 2 trial planned.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Approved
Approved
FDA approval announced December 1, 2020.
Tradipitant - EPIONE 2
Atopic dermatitis
Phase 3
Phase 3
Phase 3 enrolment commenced October 2019. On hold due to COVID-19.
Tradipitant
Motion sickness
Phase 3
Phase 3
Phase 3 new enrolment on hold due to COVID-19.
Tradipitant - EPIONE 1
Atopic dermatitis
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - February 25, 2020.
HETLIOZ (tasimelteon)
Jet Lag Disorder
CRL
CRL
CRL issued August 19, 2019.
HETLIOZ (tasimelteon)
Insomnia
Approved
Approved
Approved January 31, 2014.

Latest News

  1. WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients.

    Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint. The study was designed to determine whether tradipitant plus standard of care is superior to placebo plus standard of care in treating hospitalized patients with COVID-19 pneumonia who required supplemental oxygen support. The primary endpoint of the study is the difference between treatment and placebo on time to 2-point improvement on a 7-point…

    WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients.

    Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint. The study was designed to determine whether tradipitant plus standard of care is superior to placebo plus standard of care in treating hospitalized patients with COVID-19 pneumonia who required supplemental oxygen support. The primary endpoint of the study is the difference between treatment and placebo on time to 2-point improvement on a 7-point ordinal scale. Treatment duration was 14 days and evaluation for the primary endpoint was at Day 28. Additional secondary endpoints include other changes in clinical and laboratory status.

    An independent data and safety monitoring board (DSMB) met to assess the planned interim analysis results. The DSMB determined that the study is unlikely to show a significant difference between treatment arms at the pre-specified primary endpoint and recommended termination of the study for futility. The DSMB also determined that there are no safety concerns that contributed to its recommendation. The ODYSSEY study was initiated in April 2020 with an enrollment goal of 324 patients of which 153 have enrolled to date.

    Separately, Vanda will continue the genetics component of the study with the goal of identifying genetic susceptibility factors contributing to the incidence of severe pneumonia among patients infected with the SARS-CoV-2 virus. In pursuit of that goal, Vanda has recently reported in the Journal of Global Antimicrobial Resistance on loss of function mutations in the IFNAR2 gene associated with COVID-19 severe infection susceptibility.1

    For more information on the trial visit clinicaltrials.gov and search NCT04326426.

    References

    1. Smieszek, S.P., Polymeropoulos, V.M., Xiao, C., Polymeropoulos, C.M., Polymeropoulos, M.H. (2021). Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility. Journal of Global Antimicrobial Resistance, S2213-7165(21)00156-9. Advance online publication. https://doi.org/10.1016/j.jgar.2021.06.005

    About Tradipitant

    Tradipitant is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. Tradipitant is currently in clinical development for gastroparesis, COVID-19 pneumonia, motion sickness and atopic dermatitis. The FDA has imposed a partial clinical hold on tradipitant clinical protocols of longer than 12 weeks duration.

    About Vanda Pharmaceuticals Inc.

    Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    Various statements in this press release, including, but not limited to statements regarding Vanda's genetic analysis of SARS-CoV-2 virus patients, are "forward-looking statements" under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, new information learned in in further analysis of ODYSSEY study data, and Vanda's ability to complete the genetics component of the study. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

    All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Corporate Contact:

    AJ Jones II

    Chief Corporate Affairs and Communications Officer

    Vanda Pharmaceuticals Inc.

    202-734-3400

    Elizabeth Van Every

    Head of Corporate Affairs

    Vanda Pharmaceuticals Inc.

    202-734-3400

    Cision View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-closes-enrollment-in-the-odyssey-study-comparing-tradipitant-and-placebo-in-hospitalized-covid-19-pneumonia-patients-301346549.html

    SOURCE Vanda Pharmaceuticals Inc.

    View Full Article Hide Full Article
  2. WASHINGTON, July 28, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021.

    "Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs. Our tradipitant in gastroparesis program is nearing completion, bringing us closer to a much-needed new treatment option for patients with gastroparesis and a potentially transformational commercial opportunity for Vanda," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.

    Financial Highlights  

    Second Quarter of 2021

    • Total net product sales from HETLIOZ® and Fanapt® were $67.9 million in the…

    WASHINGTON, July 28, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021.

    "Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs. Our tradipitant in gastroparesis program is nearing completion, bringing us closer to a much-needed new treatment option for patients with gastroparesis and a potentially transformational commercial opportunity for Vanda," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.

    Financial Highlights  

    Second Quarter of 2021

    • Total net product sales from HETLIOZ® and Fanapt® were $67.9 million in the second quarter of 2021, a 9% increase compared to $62.2 million in the second quarter of 2020.
    • HETLIOZ® net product sales were $44.5 million in the second quarter of 2021, a 7% increase compared to $41.6 million in the second quarter of 2020.
    • Fanapt® net product sales were $23.4 million in the second quarter of 2021, a 13% increase compared to $20.6 million in the second quarter of 2020.
    • Income before taxes was $12.6 million in the second quarter of 2021 compared to $11.1 million in the second quarter of 2020.

    First Six Months of 2021

    • Total net product sales from HETLIOZ® and Fanapt® were $130.6 million in the first six months of 2021, a 9% increase compared to $120.2 million in the first six months of 2020.
    • HETLIOZ® net product sales were $83.9 million in the first six months of 2021, a 9% increase compared to $76.9 million in the first six months of 2020.
    • Fanapt® net product sales were $46.7 million in the first six months of 2021, an 8% increase compared to $43.3 million in the first six months of 2020.
    • Income before taxes was $23.0 million in the first six months of 2021 compared to $12.3 million in the first six months of 2020.
    • Cash, cash equivalents and marketable securities (Cash) was $396.5 million as of June 30, 2021, representing an increase to Cash of $56.6 million compared to June 30, 2020.

    Key Operational Highlights

    Tradipitant

    • The Phase III clinical study of tradipitant in gastroparesis is nearing completion with 95% of the target 200 patients already enrolled. Results are expected by the end of 2021.

    HETLIOZ® (tasimelteon)

    • A Phase III clinical study of HETLIOZ® in delayed sleep phase disorder (DSPD) is currently enrolling patients.

    Fanapt® (iloperidone)

    • A Phase III clinical study of Fanapt® in bipolar disorder is currently enrolling patients.
    • A clinical pharmacology study of the long acting injectable (LAI) formulation of Fanapt® is ongoing.

    Key Publications

    • The article "Tasimelteon safely and effectively improves sleep in Smith–Magenis syndrome: a double-blind randomized trial followed by an open-label extension" was published in July 2021 in Genetics in Medicine.1

    GAAP Financial Results

    Income before taxes was $12.6 million in the second quarter of 2021 compared to $11.1 million in the second quarter of 2020. Net income was $9.7 million in the second quarter of 2021 compared to net income of $8.7 million in the second quarter of 2020. Diluted net income per share was $0.17 in the second quarter of 2021 compared to diluted net income per share of $0.16 in the second quarter of 2020.

    Income before taxes was $23.0 million in the first six months of 2021 compared to $12.3 million in the first six months of 2020. Net income was $18.3 million in the first six months of 2021 compared to net income of $9.2 million in the first six months of 2020. Diluted net income per share was $0.32 in the first six months of 2021 compared to diluted net income per share of $0.17 in the first six months of 2020.

    2021 Financial Guidance

    Vanda expects to achieve the following financial objectives in 2021:

    Full Year 2021

    Financial Objectives

    Full Year 2021

    Guidance

    Total revenues

    $270 to $300 million

    HETLIOZ® net product sales

    $180 to $200 million

    Fanapt® net product sales

    $90 to $100 million

    Year-end 2021 Cash

    Greater than $400 million

    Conference Call

    Vanda has scheduled a conference call for today, Wednesday, July 28, 2021, at 4:30 PM ET. During the call, Vanda's management will discuss the second quarter 2021 financial results and other corporate activities. Investors can call 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 5298904. A replay of the call will be available on Wednesday, July 28, 2021, beginning at 7:30 PM ET and will be accessible until Wednesday, August 4, 2021 at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 5298904.

    The conference call will be broadcast simultaneously on Vanda's website, www.vandapharma.com. Investors should click on the Investors tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda's website for a period of 30 days.

    References

    1. Polymeropoulos, C.M., Brooks, J., Czeisler, E.L., Fisher, M.A., Gibson, M.M., Kite, K., Smieszek, S.P., Xiao, C., Elsea, S.H., Birznieks, G., Polymeropoulos, M.H. (2021). Tasimelteon safely and effectively improves sleep in Smith–Magenis syndrome: a double-blind randomized trial followed by an open-label extension. Genetics in Medicine. https://doi.org/10.1038/s41436-021-01282-y

    About Vanda Pharmaceuticals Inc.

    Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

    CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

    Various statements in this press release, including, but not limited to, the guidance provided under "2021 Financial Guidance" above and statements regarding the clinical development and regulatory timelines and commercial potential for tradipitant are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's assumptions regarding its ability to continue to grow its business in the U.S., Vanda's ability to complete the clinical development and obtain regulatory approval for tradipitant in the treatment of gastroparesis, the prevalence of gastroparesis and Vanda's ability to successfully commercialize tradipitant. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

    All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

     

    VANDA PHARMACEUTICALS INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except for share and per share amounts)

    (unaudited)





    Three Months Ended



    Six Months Ended



    June 30

    2021



    June 30

    2020



    June 30

    2021



    June 30

    2020

    Revenues:















    HETLIOZ® net product sales

    $

    44,509





    $

    41,561





    $

    83,852





    $

    76,897



    Fanapt® net product sales

    23,390





    20,646





    46,716





    43,310



    Total revenues

    67,899





    62,207





    130,568





    120,207



    Operating expenses:















    Cost of goods sold excluding amortization

    6,566





    5,847





    12,596





    11,054



    Research and development

    20,248





    12,903





    36,379





    28,430



    Selling, general and administrative

    28,347





    33,917





    58,144





    70,938



    Intangible asset amortization

    369





    369





    739





    739



    Total operating expenses

    55,530





    53,036





    107,858





    111,161



    Income from operations

    12,369





    9,171





    22,710





    9,046



    Other income

    235





    1,918





    322





    3,284



    Income before income taxes

    12,604





    11,089





    23,032





    12,330



    Provision for income taxes

    2,951





    2,375





    4,729





    3,130



    Net income

    $

    9,653





    $

    8,714





    $

    18,303





    $

    9,200



    Net income per share, basic

    $

    0.17





    $

    0.16





    $

    0.33





    $

    0.17



    Net income per share, diluted

    $

    0.17





    $

    0.16





    $

    0.32





    $

    0.17



    Weighted average shares outstanding, basic

    55,582,916





    54,501,308





    55,365,558





    54,153,812



    Weighted average shares outstanding, diluted

    56,903,340





    55,081,397





    56,705,419





    54,975,771





     

    VANDA PHARMACEUTICALS INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)





    June 30

    2021



    December 31

    2020

    ASSETS







    Current assets:







    Cash and cash equivalents

    $

    57,242





    $

    61,031



    Marketable securities

    339,251





    306,709



    Accounts receivable, net

    37,090





    30,036



    Inventory

    1,055





    1,280



    Prepaid expenses and other current assets

    12,014





    10,089



    Total current assets

    446,652





    409,145



    Property and equipment, net

    3,631





    4,136



    Operating lease right-of-use assets

    9,898





    10,459



    Intangible assets, net

    20,820





    21,559



    Deferred tax assets

    78,641





    81,516



    Non-current inventory and other

    8,003





    6,641



    Total assets

    $

    567,645





    $

    533,456



    LIABILITIES AND STOCKHOLDERS' EQUITY







    Current liabilities:







    Accounts payable and accrued liabilities

    $

    31,788





    $

    31,509



    Product revenue allowances

    40,201





    34,427



    Total current liabilities

    71,989





    65,936



    Operating lease non-current liabilities

    10,740





    11,497



    Other non-current liabilities

    3,696





    2,757



    Total liabilities

    86,425





    80,190



    Stockholders' equity:







    Common stock

    56





    55



    Additional paid-in capital

    660,086





    650,300



    Accumulated other comprehensive income

    103





    239



    Accumulated deficit

    (179,025)





    (197,328)



    Total stockholders' equity

    481,220





    453,266



    Total liabilities and stockholders' equity

    $

    567,645





    $

    533,456



     

    Corporate Contact:

    AJ Jones II

    Chief Corporate Affairs and Communications Officer

    Vanda Pharmaceuticals Inc.

    202-734-3400

     

    Elizabeth Van Every

    Head of Corporate Affairs

    Vanda Pharmaceuticals Inc.

    202-734-3400

     

     



     

    Cision View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-second-quarter-2021-financial-results-301343567.html

    SOURCE Vanda Pharmaceuticals Inc.

    View Full Article Hide Full Article
  3. NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire P.C. announces the proposed settlement of the derivative action captioned In re Vanda Pharmaceuticals Inc. Derivative Litigation, Case No. 1:19-cv-04293-FB-LB in the United States District Court for the Eastern District of New York.

    If you were a stockholder of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as of July 19, 2021 and continue to own such shares, please click HERE to read the Notice to Current Vanda Stockholders, which contains important information regarding your rights.

    Please reach out to counsel for Plaintiffs with any questions or concerns at:

    Counsel for Plaintiffs:
    Gregory M. Nespole
    Daniel Tepper
    LEVI & KORSINSKY, LLP
    55 Broadway, 10th Floor
    New York NY 10006…

    NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire P.C. announces the proposed settlement of the derivative action captioned In re Vanda Pharmaceuticals Inc. Derivative Litigation, Case No. 1:19-cv-04293-FB-LB in the United States District Court for the Eastern District of New York.

    If you were a stockholder of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) as of July 19, 2021 and continue to own such shares, please click HERE to read the Notice to Current Vanda Stockholders, which contains important information regarding your rights.

    Please reach out to counsel for Plaintiffs with any questions or concerns at:

    Counsel for Plaintiffs:

    Gregory M. Nespole

    Daniel Tepper

    LEVI & KORSINSKY, LLP

    55 Broadway, 10th Floor

    New York NY 10006

    Fax: (212) 363-7171

    W. Scott Holleman

    Garam Choe

    BRAGAR EAGEL & SQUIRE, P.C.

    810 Seventh Avenue, Suite 620

    New York, NY 10019

    Fax: (212) 486-0462



    Primary Logo

    View Full Article Hide Full Article
  4. WASHINGTON, July 21, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the market closes.

    Vanda will host a conference call at 4:30 PM ET on Wednesday, July 28, 2021, during which management will discuss the second quarter 2021 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 5298904.

    The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary…

    WASHINGTON, July 21, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the market closes.

    Vanda will host a conference call at 4:30 PM ET on Wednesday, July 28, 2021, during which management will discuss the second quarter 2021 financial results and other corporate activities. To participate in the conference call, please dial 1-866-688-9426 (domestic) or 1-409-216-0816 (international) and use passcode 5298904.

    The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

    A replay of the call will be available on Wednesday, July 28, 2021, beginning at 7:30 PM ET and will be accessible until Wednesday, August 4, 2021, at 7:30 PM ET. The replay call-in number is 1-855-859-2056 for domestic callers and 1-404-537-3406 for international callers. The passcode number is 5298904.

    About Vanda Pharmaceuticals Inc.

    Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

    Corporate Contact:

    AJ Jones II

    Chief Corporate Affairs and Communications Officer

    Vanda Pharmaceuticals Inc.

    202-734-3400

    Elizabeth Van Every

    Head of Corporate Affairs

    Vanda Pharmaceuticals Inc.

    202-734-3400

    Cision View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-announce-second-quarter-2021-financial-results-on-july-28-2021-301338914.html

    SOURCE Vanda Pharmaceuticals Inc.

    View Full Article Hide Full Article
  5. WASHINGTON, May 12, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Vanda's management will participate at the following investor conferences:

    Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 AM ET.

    Oppenheimer Virtual Rare & Orphan Disease Summit on Friday, May 21, 2021 at 2:05 PM ET.

    Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:00 PM ET.

    The Bank of America, Oppenheimer, and Jefferies conferences may be accessed live on Vanda's corporate website, www.vandapharma.com.  Investors should click on the Investors tab and follow the links under Recent Events.  Investors are advised to go to the conference websites at least 15 minutes…

    WASHINGTON, May 12, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Vanda's management will participate at the following investor conferences:

    Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 AM ET.

    Oppenheimer Virtual Rare & Orphan Disease Summit on Friday, May 21, 2021 at 2:05 PM ET.

    Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:00 PM ET.

    The Bank of America, Oppenheimer, and Jefferies conferences may be accessed live on Vanda's corporate website, www.vandapharma.com.  Investors should click on the Investors tab and follow the links under Recent Events.  Investors are advised to go to the conference websites at least 15 minutes early to register, download, and install any necessary software or presentations. Links to the archived conferences will be available on Vanda's website for a period of approximately 30 days.

    About Vanda Pharmaceuticals Inc.

    Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

    Corporate Contact:

    AJ Jones II

    Chief Corporate Affairs and Communications Officer

    Vanda Pharmaceuticals Inc.

    (202) 734-3400

    Elizabeth Van Every

    Head of Corporate Affairs

    Vanda Pharmaceuticals Inc.

    (202) 734-3400

     

    Cision View original content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-at-upcoming-2021-investor-conferences-301290225.html

    SOURCE Vanda Pharmaceuticals Inc.

    View Full Article Hide Full Article
View All Vanda Pharmaceuticals Inc. News